Lantheus Holdings, Inc. Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)
Lantheus Holdings, Inc. (LNTH) reported Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) of $1.20 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss · last filed 2025-02-26
- Lantheus Holdings, Inc. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for the quarter ending 2024-12-31 was $1.10M, a 450.00% increase year-over-year.
- Lantheus Holdings, Inc. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for the quarter ending 2024-09-30 was $0.00.
- Lantheus Holdings, Inc. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for the quarter ending 2023-12-31 was $200.00K.
- Lantheus Holdings, Inc. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for the quarter ending 2023-09-30 was -$600.00K, a 140.00% decline year-over-year.
- Lantheus Holdings, Inc. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for fiscal 2024 was $1.20M.
- Lantheus Holdings, Inc. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for fiscal 2023 was -$9.30M.
- Lantheus Holdings, Inc. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for fiscal 2022 was -$34.70M.
- Lantheus Holdings, Inc. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for fiscal 2021 was -$72.40M, a 3720.00% decline from fiscal 2020.
| Period end | Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) 3 month | Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) 6 month | Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) 9 month | Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2024-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $1.10M derived: sum of 2 quarters · filed 2025-02-26 | $1.20M 10-K · filed 2025-02-26 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $100.00K 10-Q · filed 2024-11-06 | ||
| 2024-06-30 | $100.00K 10-Q · filed 2024-07-31 | |||
| 2023-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$400.00K derived: sum of 2 quarters · filed 2024-02-22 | -$7.90M derived: sum of 3 quarters · filed 2024-02-22 | -$9.30M 10-K · filed 2024-02-22 |
| 2023-09-30 | -$600.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$8.10M derived: sum of 2 quarters · filed 2023-11-02 | -$9.50M 10-Q · filed 2023-11-02 | -$18.80M derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | -$7.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$8.90M 10-Q · filed 2023-08-03 | -$18.20M derived: sum of 3 quarters · filed 2023-08-03 | -$16.70M derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | -$1.40M 10-Q · filed 2023-05-04 | -$10.70M derived: sum of 2 quarters · filed 2023-05-04 | -$9.20M derived: sum of 3 quarters · filed 2023-05-04 | -$17.70M derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | -$9.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$7.80M derived: sum of 2 quarters · filed 2023-02-23 | -$16.30M derived: sum of 3 quarters · filed 2023-02-23 | -$34.70M 10-K · filed 2023-02-23 |
| 2022-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$7.00M derived: sum of 2 quarters · filed 2022-11-03 | -$25.40M 10-Q · filed 2022-11-03 | -$69.30M derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | -$8.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$26.90M 10-Q · filed 2022-08-04 | -$70.80M derived: sum of 3 quarters · filed 2022-08-04 | -$73.40M derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | -$18.40M 10-Q · filed 2022-04-29 | -$62.30M derived: sum of 2 quarters · filed 2022-04-29 | -$64.90M derived: sum of 3 quarters · filed 2022-04-29 | -$90.50M derived: sum of 4 quarters · filed 2022-04-29 |
| 2021-12-31 | -$43.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$46.50M derived: sum of 2 quarters · filed 2022-02-24 | -$72.10M derived: sum of 3 quarters · filed 2022-02-24 | -$72.40M 10-K · filed 2022-02-24 |
| 2021-09-30 | -$2.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$28.20M derived: sum of 2 quarters · filed 2021-11-04 | -$28.50M 10-Q · filed 2021-11-04 | -$27.30M derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | -$25.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-28 | -$25.90M 10-Q · filed 2021-07-28 | -$24.70M derived: sum of 3 quarters · filed 2021-07-28 | -$23.90M derived: sum of 4 quarters · filed 2021-07-28 |
| 2021-03-31 | -$300.00K 10-Q · filed 2021-05-04 | $900.00K derived: sum of 2 quarters · filed 2021-05-04 | $1.70M derived: sum of 3 quarters · filed 2021-05-04 | $1.70M derived: sum of 4 quarters · filed 2021-05-04 |
| 2020-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $2.00M derived: sum of 2 quarters · filed 2021-02-25 | $2.00M derived: sum of 3 quarters · filed 2021-02-25 | $2.00M 10-K · filed 2021-02-25 |
| 2020-09-30 | $800.00K 10-Q · filed 2020-11-05 | $800.00K derived: sum of 2 quarters · filed 2020-11-05 | $800.00K 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $0.00 10-Q · filed 2020-07-31 | $0.00 10-Q · filed 2020-07-31 | ||
| 2020-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |